|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 恩替卡韦与拉米夫定治疗HBeAg阴性慢性乙型肝炎的对照研究显示文摘Ⅱ期临床试验已经证实恩替卡韦是一种治疗HBeAg阴性慢性乙型肝炎有效和可选择的抗病毒药物。采用双盲法将648例未曾接受过核苷类药物治疗的HBeAg阴性慢性乙型肝炎随机分配进入恩替卡韦(0.5mg/d)治疗组或拉米夫定(100mg/d)治疗组,疗程至少52wk。 | Lai CL Shouval D Lok AS 陈楠(摘译) 张占卿(审校) | 2006 | 世界感染杂志2006，6，4： | 197 |
| 2 | Trans-arterial chemo-embolization is safe and effective for very elderly patients with hepatocellular carcinoma显示文摘AIM: To assess the safety and efficacy of trans-arterial chemo-embolization (TACE) in very elderly patients. METHODS: A prospective cohort study, from 2001 to 2010, compared clinical outcomes following TACE between patients ≥ 75 years old and younger patients (aged between 65 and 75 years and younger than 65 years) with hepatocellular carcinoma (HCC), diagnosed according to the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases criteria. The decision that patients were not candidates for curative therapy was made by a multidisciplinary HCC team. Data collected included demographics, co-morbidities, liver disease etiology, liver disease severity and the number of procedures. The primary outcome was mortality; secondary outcomes included post-embolization syndrome (nausea, fever, abdominal right upper quadrant pain, increase in liver enzymes with no evidence of sepsis and with a clinical course limited to 3-4 d post procedure) and 30-d complications. Additionally, changes in liver enzyme measurements were assessed [alanine and aspartate aminotransferase (ALT and AST), gamma-glutamyl transpeptidase and alkaline phosphatase] in the week following TACE. Analysis employed both univariate and multivariate methods (Cox regression models). RESULTS: Of 102 patients who underwent TACE as sole treatment, 10 patients (9.8%) were > 80 years old at diagnosis; 13 (12.7%) were between 75 and 80 years, 45 (44.1%) were between 65 and 75 years and 34 (33.3%) were younger than 65 years. Survival analysis demonstrated similar survival patterns between the elderly patients and younger patients. Age was also not associated with the adverse event rate. Survival rates at 1, 2 and 3 years from diagnosis were 74%, 37% and 31% among patients < 65 years; 83%, 66% and 48% among patients aged 65 to 75 years; and 86%, 41% and 23% among patients ≥ 75 years. There were no differences between the age groups in the pre-procedural care, including preventive treatment for contrast nephropathy and prophylactic antibiotics. Multivariate survival analysis, controlling for disease stage at diagnosis with the Barcelona Clinic Liver Cancer score, number of TACE procedures, sex and alphafetoprotein level at the time of diagnosis, found no significant difference in the mortality hazard for elderly vs younger patients, and there were no differences in post-procedural complications. Serum creatinine levels did not change after 55% of the procedures, in all age groups. In 42% of all procedures, serum creatinine levels increased by no more than 25% above the baseline levels prior to TACE. Overall, there were 69 post-embolization events (23%). Hepatocellular enzymes often increased following TACE, with no association with prognosis. In 40% of the procedures, ALT and AST levels rose by at least 100%. The increases in hepatocellular enzymes occurred similarly in all age groups. CONCLUSION: TACE is safe and effective in very elderly patients with HCC, and is not associated with decreased survival or increased complication rates. | Matan J Cohen Allan I Bloom Orly Barak Alexander Klimov Tova Nesher Daniel Shouval Izhar Levi Oren Shibolet | 2013 | World Journal of Gastroenterology2013，19，16： | 13 |
| 3 | 恩替卡韦与拉米夫定治疗HBeAg阴性慢性乙型肝炎的比较显示文摘BACKGROUND:Entecavir is a potent and selective antiviral agent that has demonstrated efficacy in phase 2 studies in patients with hepatitis B e antigen(HBeAg)-negative chronic hepatitis B.METHODS:In this phase 3,double-blind trial,we randomly assigned 648 patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue to receive 0.5 mg of entecavir or 100 mg of lamivudine once daily for a minimum of 52 weeks.The primary efficacy end point was histologic improvement(a decrease by at least two points in the Knodell necroinflammatory score,without worsening of fibrosis).RESULTS:Histologic improvement after 48 weeks of treatment occurred in 208 of 296 patients in the entecavir group who had adequate baseline liver-biopsy specimens that could be evaluated(70 percent),as compared with 174 of 287 such patients in the lamivudine group(61 percent,P=0.01).More patients in the entecavir group than in the lamivudine group had undetectable serum hepatitis B virus(HBV)DNA levels according to a polymerase-chain-reaction assay(90 percent vs.72 percent,P < 0.001)and normalization of alanine aminotransferase levels(78 percent vs.71 percent,P = 0.045).The mean reduction in serum HBV DNA levels from baseline to week 48 was greater with entecavir than with lamivudine(5.0 vs.4.5 log on a base-10 scale copies per milliliter,P < 0.001).There was no evidence of resistance to entecavir.Safety and adverse-event profiles were similar in the two groups.CONCLUSIONS:Among patients with HBeAg-negative chronic hepatitis B who had not previously been treated with a nucleoside analogue,the rates of histologic improvement,virologic response,and normalization of alanine aminotransferase levels were significantly higher at 48 weeks with entecavir than with lamivudine.The safety profile of the two agents was similar,and there was no evidence of viral resistance to entecavir. | Shouval D. Lok A.S. 王晓君 | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，2，9： | 5 |
| 4 | Immunosuppression and HBV Reactivation显示文摘 | Daniel Shouval Oren Shibolet | 2013 | Semin Liver Dis2013，，02： | 3 |
| 5 | Screening, prevention and treat- ment of viral hepatitis B reactivation in patients with haemato- logical malignaneies显示文摘 | Lalazar G Rund D Shouval D | 2007 | Br J Haematol2007，136，： | 1 |
| 6 | Site-specific disease potential of individual Streptococcus pneumoniae serotypes in pediatric invasive disease,acute otitis media and acute conjunctivitis显示文摘 | Shouval DS Greenberg D Givon-Lavi N | 2006 | Pediatr Infect Dis J2006，25，7： | 1 |
| 7 | Screening,preventionand treatment of viral hepatitis B reactivation inpatients with haematological malignancies review显示文摘 | Lalazar G Rund D Shouval D | 2007 | Br J Haematol2007，136，5： | 1 |
| 8 | Strategies for global prevention of hepatitis B virus infection 显示文摘 | Van Damme P Zanetti AR Shouval D | 2010 | Adv Exp MedBiol2010，659，： | 1 |
| 9 | Regulation of autophagy by ROS : physiology and pathology 显示文摘 | Scherz - Shouval R Elazar Z | 2011 | Trends Biochem Sci2011，36，1： | 1 |
| 10 | Visual experience and deprivation bidirectionally modify the composition and function of NMDA receptors in visual cortex显示文摘 | Philpot B D Sekhar A K Shouval H Z | 2001 | Neuron2001，29，： | 1 |
| 11 | The global impact of vaccination against hepatitis B : a historical overview 显示文摘 | Zanetti AR Van Damme P Shouval D | 2008 | Vaccine2008，26，49： | 1 |
| 12 | Cell adhesion molecules and hyaluronic acid as markers of inflammation, fibrosis and response to antiviral therapy in chronic hepatitis C patients显示文摘 | Granot E Shouval D Ashur Y | 2001 | Mediators Inflamm2001，10，5： | 1 |
| 13 | Respiratory syncytial virus-positive bronchiolitis in hospitalized infants is associat- ed with thrombocytosis显示文摘 | Bilavsky E Yarden-Bilavsky H Shouval DS | 2010 | Isr Med Assoc J2010，12，1： | 1 |
| 14 | IL-1 is required for tumor invasiveness and angiogenesis显示文摘 | Voronov E Shouval DS Krelin Y | 2003 | Proc Natl Acad Sci2003，100，5： | 1 |
| 15 | IL-1 is required for tumor invasiveness and angiogenesis 显示文摘 | Voronov E Shouval DS Krelin Y | 2003 | Proc Natl Acad Sci USA2003，100，5： | 1 |
| 16 | A study of HBsAg carriers in Israel显示文摘 | Shouval D Tur-Kaspa R Manny N | 1981 | Israel J Med Sci1981，17，： | 1 |
| 17 | Hyper-IL-6 Gene Therapy Reverse Fulminant Hepatic Failure显示文摘 | Hecht N Pappo O Shouval D | 2001 | Molecular Therapy2001，3，5： | 1 |
| 18 | Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine 显示文摘 | Rendi-Wagner P Shouval D Genton B | 2006 | Vaccine2006，24，15： | 1 |
| 19 | Role in nude mice of interferon and natural killer cells in inhibiting the tumorigenicity of human hepatocellular carcinoma cells infected with hepatitis B virus显示文摘 | Shouval D Rager-Zisman B Quan P | 1983 | J Clin Invest1983，72，2： | 1 |
| 20 | Tumorigenicity in nude mice of a human hepatoma cell line containing hepatitis B virus DNA显示文摘 | Shouval D Reid LM Chakraborty PR | 1981 | Cancer Res1981，41，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员